✕
Free ₹200 worth HealthCash on app
Use HealthCash to order medicines, health products & much more
Oncotar 1000 mg Injection
Manufactured byUnited Biotech Pvt. Ltd.
ContainsCytarabine
CURRENTLY UNAVAILABLE
Confused about any medicine? Just ask Practo AIFREE
50000+ health queries resolved in last month
Chat with Practo AI on Whatsapp
Not finding what you need? Ask Practo AI
FREE
Chat with Practo AI on Whatsapp
Description
Oncotar 1000 mg Injection is an anti-cancer medicine that contains cytarabine. It is used in the treatment of various types of blood and bone marrow cancers such as acute non-lymphocytic leukaemia (a type of cancer with excess immature white blood cells) and acute lymphocytic leukaemia (a type of cancer that affects white blood cells). It should only be used under medical supervision.
Oncotar 1000 mg Injection shows some side effects like hair loss, skin and mouth ulcers, rash, anaemia, sepsis (blood poisoning), low white blood cell count, nausea, vomiting, abdominal pain, pneumonia, infections, fever, anal ulcers, abnormal liver function and stomatitis (Inflammation of the mouth). Oncotar 1000 mg Injection does not cause drowsiness but it still may cause side effects that affect your ability to drive. Inform your doctor immediately if you feel sudden chills, notice unusual bruising or bleeding and black and tarry stools.
Oncotar 1000 mg Injection is not recommended for use in elderly patients. Inform your doctor if you have liver or kidney diseases before receiving this medicine. Close monitoring of liver function and the blood cell count is necessary while receiving this medication as it is known to affect the liver and bone marrow. Oncotar 1000 mg Injection is not recommended for use in pregnancy and breastfeeding.
QUICK LINKS:
Substitutes
List of substitutes for Oncotar 1000 mg Injection
Side effects
Major & minor side effects for Oncotar 1000 mg Injection
Nausea
Vomiting
Diarrhoea
Rash
Fever
Elevated Liver Enzymes
Bleeding
Headache
Chest pain
Joint pain
Anal ulcers
Skin ulcers
Hair loss
Anemia
Uses of Oncotar 1000 mg Injection
What is it prescribed for?
Acute Lymphocytic Leukemia
Oncotar 1000 mg Injection is used for the treatment of acute lymphocytic leukaemia (a type of cancer of the blood and the bone marrow) that affects white blood cells in adults and children.
Acute Non Lymphocytic Leukemia
Oncotar 1000 mg Injection is used for the treatment of Acute non-lymphocytic leukaemia which is a cancer of the blood and the bone marrow with myeloblasts (immature white blood cells) in adults.
Concerns
Commonly asked questions
How long does it take for this medicine to take effect?
The amount of time required for Oncotar 1000 mg Injection to show its action within 15 minutes after administration.How long do the effects of this medicine last?
Oncotar 1000 mg Injection remains active in the body for the duration of 12-24 hours.Is it safe to consume alcohol while taking this medicine?
Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.Is this a habit forming medicine?
No habit-forming tendencies were reported.Can this medicine be taken during pregnancy?
Oncotar 1000 mg Injection is not recommended for use in pregnancy, because it may harm your foetus.Can this medicine be taken while breast-feeding?
Oncotar 1000 mg Injection is not recommended for use in breastfeeding women because it may cause undesirable effects in infants.
Allergy
Avoid receiving Oncotar 1000 mg Injection if you have a known allergy to cytarabine, or any other inactive ingredients present in this formulation. Inform your doctor, if you notice any symptoms of serious allergic reactions such as skin rash, itching/swelling (especially of the face/tongue/throat), severe dizziness or breathing difficulty, etc.
Warnings for special population
Pregnancy
Oncotar 1000 mg Injection is not recommended for use in pregnancy, because it may harm your foetus.
Breast-feeding
Oncotar 1000 mg Injection is not recommended for use in breastfeeding women because it may cause undesirable effects in infants.
General warnings
Use in Elderly
Oncotar 1000 mg Injection is not recommended to use in elderly patients as they can not tolerate drug toxicity.
Liver Disease
Oncotar 1000 mg Injection should be used with caution if you have liver diseases due to the increased risk of adverse effects. Your doctor may monitor your liver function regularly while receiving this medicine. Your doctor may adjust the dose if required based on your clinical conditions.
Driving or Operating machinery
Oncotar 1000 mg Injection may cause dizziness in some patients. It is advised that you do not perform any activities such as driving a vehicle or operating machinery if you experience any dizziness during treatment with this medicine.
Bone marrow suppression
Oncotar 1000 mg Injection should be used with caution since it may increase the risk of myelosuppression (decreased bone marrow function). Regular monitoring of blood cell count is necessary while receiving this medicine. Your doctor may adjust the dose if required based on your clinical conditions.
Missed Dose
Since Oncotar 1000 mg Injection is usually administered by a qualified healthcare professional in the clinical/hospital setting, the likelihood of missing a dose is very low.
Overdose
Since Oncotar 1000 mg Injection is administered in the hospital setting by a qualified healthcare professional, the likelihood of an overdose is very less. However, emergency medical treatment will be initiated by the doctor if an overdose is suspected.
All drugs interact differently for person to person. You should check all the possible interactions with your doctor before starting any medicine.
Interaction with Alcohol
Description
Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
Instructions
Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
Interaction with Medicine
Thalidomide
Adalimumab
Digoxin
Methotrexate
Cyclophosphamide
Naltrexone
Vinblastine
Disease interactions
Infections
Oncotar 1000 mg Injection should be used with extreme caution if you have a history of recurrent infections due to the increased risk of myelosuppression (a condition in which bone marrow activity is decreased). Initiation of therapy with this medicine in patients with active infections is not recommended. Your doctor may monitor your condition while on treatment with this medicine if you have active infections.
Food interactions
Information not available.
Lab interactions
Information not available.
Oncotar 1000 mg Injection is usually administered in the clinical/hospital setting under the supervision of a qualified healthcare professional. Follow all the instructions given by your doctor after receiving this injection.
Inform the doctor if you have a known allergy to Oncotar 1000 mg Injection. Report all your current medicines as well as your medical conditions to the doctor before receiving this medicine.
Use reliable contraception methods to prevent pregnancy if you are using Oncotar 1000 mg Injection.
Consult your doctor if you notice any fever, sore throat, rash or severe diarrhoea which may be signals of infection caused by using this medicine.
Miscelleneous
How it works
Oncotar 1000 mg Injection prevents the growth and spread of cancer cells in your body by interfering with the growth of DNA and RNA of the cancer cells.
Legal Status
Classification
Category
Antimetabolites
Schedule
Schedule H
Pfizer.com. 2021. [online] Available at: < [Accessed 23 August 2021].
Medicines.org.uk. 2021. Cytarabine Injection Solution 100 mg/ml - Summary of Product Characteristics (SmPC) - (emc). [online] Available at: < [Accessed 23 August 2021].
Ebs.tga.gov.au. 2021. TGA eBS - Product and Consumer Medicine Information Licence. [online] Available at: < [Accessed 23 August 2021].
Related Questions
Information on this page was last updated on 27 Aug 2021
Disclaimer
We’ve made all possible efforts to ensure that the information provided here is accurate, up-to-date and complete, however, it should not be treated as a substitute for professional medical advice, diagnosis or treatment. Practo only provides reference source for common information on medicines and does not guarantee its accuracy or exhaustiveness. The absence of a warning for any drug or combination thereof, should not be assumed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Practo does not assume any responsibility for any aspect of healthcare administered with the aid of information provided above. If you have any doubts about your medication then we strongly recommend that you consult with your doctor, nurse or healthcare provider. See detailed T&C here.